To Demonstrate the Relative Bioavailability of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed and Fasted Conditions
Comparative, Randomized, 3-way Crossover Bioavailability Study of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules In Health Adult Males Under Fed and Fasted Conditions
1 other identifier
interventional
18
0 countries
N/A
Brief Summary
To demonstrate the relative bioavailability of Geneva and Basel (Anafranil) 25 mg Clomipramine Hydrochloride capsules under fed and fasted conditions.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_1 depression
Started Apr 1994
Shorter than P25 for phase_1 depression
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 1994
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 1994
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 1994
CompletedFirst Submitted
Initial submission to the registry
June 2, 2009
CompletedFirst Posted
Study publicly available on registry
June 4, 2009
CompletedMarch 28, 2017
June 1, 2009
2 months
June 2, 2009
March 27, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Bioequivalence based on AUC and Cmax
53 days
Study Arms (3)
1
EXPERIMENTALGeneva 25 mg Clomipramine Hydrochloride Capsules Under Fasting Conditions.
2
EXPERIMENTALGeneva 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions.
3
ACTIVE COMPARATORBasel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions.
Interventions
Eligibility Criteria
You may qualify if:
- No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.
You may not qualify if:
- Positive test results for HIV or hepatitis B or C.
- Treatment for drug or alcohol dependence.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Sandozlead
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Richard Lalonde, Pharm.D.
Phoenix International Life Science Inc.
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
June 2, 2009
First Posted
June 4, 2009
Study Start
April 1, 1994
Primary Completion
June 1, 1994
Study Completion
June 1, 1994
Last Updated
March 28, 2017
Record last verified: 2009-06